What is in Eli Lilly & Company’s 2025 Year in Review Report?

Eli Lilly and Company is a global leader in the pharmaceutical sector, employing more than 50,000 people around the world.

It is known for developing and producing medications in areas such as diabetes, obesity, oncology and immunology.

Eli Lilly has published its 2025 Year in Review, outlining its financial and sustainability progress throughout the year.

Eli Lilly in 2025

In 2025, Eli Lilly and Company grew its oncology and immunology portfolios.

It launched Inluriyo for the treatment of breast cancer and received a new indication for its Omvoh treatment for Crohn’s disease.

It also completed its international rollouts of Mounjaro, as well as submitting its first oral GLP-1 orforglipron for approval in the US and more than 40 other countries.

Eli Lilly worked on building speed and innovation in its drug discovery timeline, expanding drug-making platforms including genetic medicines, siRNA and antibody-drug conjugates.

David A. Ricks, Chair and CEO of Eli Lilly, says: “2025 was an important year for Lilly and for the patients we serve.

“We advanced exciting scientific research and expanded access to our innovative medicines, growing our impact and our capacity to serve more patients worldwide.

“As we approach Lilly’s 150th anniversary in 2026, we honour our history while focusing on the opportunities that lie ahead. With scientific strength, growing scale and sustained investment in new medicines, we are determined to build on a legacy defined by improving outcomes for patients.”

Eli Lilly’s financial performance

Eli Lilly’s revenue grew 45% in 2025, as the company’s demand and performance strengthened across its global portfolio.

The company’s medication tirzepatide, sold as Mounjaro and Zepbound, became one of the world’s top-selling prescription medicines in 2025.

The medicine has been used to support and improve the lives of people living with type 2 diabetes, obesity and obstructive sleep apnoea.

Eli Lilly’s late-stage development pipeline also advanced in 2025, with more than 25 Phase 3 trials achieving positive results.

It began 12 new Phase 3 programmes across its therapeutic areas, including treatments to tackle cardiovascular disease and non-small cell lung cancer.

This aims to help the company bring critical new treatment options to even more patients around the globe.

Sustainability highlights

Throughout its entire operations in 2025, Eli Lilly kept sustainability at the centre of its work.

It created new access pathways, including an agreement to broaden the availability of obesity medicines through programmes across the US.

The company focused on expanding its direct-to-patient models, helping to increase consumer choice and affordability.

In 2025, more than one million people in the US engaged with Lilly Direct, which offers transparent pricing and an additional option for patients to locate care.

It is working on scaling this patient-first model on an international scale through working with employers and insurers to help more people access its medicines.

Eli Lilly generated and purchased approximately 80% of its electricity from renewable sources in 2025.

It also received a LEED Gold Certification for sustainable building design and construction at its Limerick manufacturing site.

David says: “Lilly’s commitment to people, the planet and society remained central to our work in 2025.

“In 2025, more than 71 million patients benefitted from Lilly medicines. We are approaching our 30x30 goal to improve quality healthcare access for 30 million people annually in resource-limited settings by 2030.

“Together, we will carry this momentum forward so that more people benefit from our medicines for generations to come. Guided by our purpose, we remain committed to getting better and better every day.”